JP2010506953A5 - - Google Patents

Download PDF

Info

Publication number
JP2010506953A5
JP2010506953A5 JP2009533511A JP2009533511A JP2010506953A5 JP 2010506953 A5 JP2010506953 A5 JP 2010506953A5 JP 2009533511 A JP2009533511 A JP 2009533511A JP 2009533511 A JP2009533511 A JP 2009533511A JP 2010506953 A5 JP2010506953 A5 JP 2010506953A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
pharmaceutical composition
acceptable carrier
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009533511A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010506953A (ja
JP5343267B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/081685 external-priority patent/WO2008049027A1/en
Publication of JP2010506953A publication Critical patent/JP2010506953A/ja
Publication of JP2010506953A5 publication Critical patent/JP2010506953A5/ja
Application granted granted Critical
Publication of JP5343267B2 publication Critical patent/JP5343267B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009533511A 2006-10-17 2007-10-17 タラロゾール代謝物 Expired - Fee Related JP5343267B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85198906P 2006-10-17 2006-10-17
US60/851,989 2006-10-17
PCT/US2007/081685 WO2008049027A1 (en) 2006-10-17 2007-10-17 Talarazole metabolites

Publications (3)

Publication Number Publication Date
JP2010506953A JP2010506953A (ja) 2010-03-04
JP2010506953A5 true JP2010506953A5 (enExample) 2010-09-16
JP5343267B2 JP5343267B2 (ja) 2013-11-13

Family

ID=39314359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533511A Expired - Fee Related JP5343267B2 (ja) 2006-10-17 2007-10-17 タラロゾール代謝物

Country Status (10)

Country Link
US (2) US8188124B2 (enExample)
EP (1) EP2114895A4 (enExample)
JP (1) JP5343267B2 (enExample)
KR (1) KR101419965B1 (enExample)
CN (1) CN101611016B (enExample)
AU (1) AU2007311026B2 (enExample)
BR (1) BRPI0718310A2 (enExample)
CA (1) CA2667053C (enExample)
MX (1) MX2009004096A (enExample)
WO (1) WO2008049027A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
RU2473685C2 (ru) 2007-07-31 2013-01-27 Лайфскен, Инк. Дифференцировка человеческих эмбриональных стволовых клеток
CN107574142B (zh) 2007-11-27 2021-07-06 生命扫描有限公司 人胚胎干细胞的分化
BRPI0908033A2 (pt) 2008-02-21 2015-08-04 Centocor Ortho Biotech Inc Método placas de superfície modificada e composições para adesão, cultura e desprendimento de célula
CA2729121C (en) 2008-06-30 2019-04-09 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
JP2012507289A (ja) 2008-10-31 2012-03-29 ヤンセン バイオテツク,インコーポレーテツド ヒト胚性幹細胞の膵内分泌系への分化
EP2346988B1 (en) 2008-10-31 2017-05-31 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
MX2011005288A (es) 2008-11-20 2011-06-01 Centocor Ortho Biotech Inc Celulas madre pluripotentes en microportadores.
CA2744227C (en) 2008-11-20 2018-10-02 Centocor Ortho Biotech Inc. Methods and compositions for cell attachment and cultivation on planar substrates
EP2456862A4 (en) 2009-07-20 2013-02-27 Janssen Biotech Inc DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS
DK2516625T3 (da) 2009-12-23 2024-09-09 Janssen Biotech Inc Differentiering af humane embryonale stamceller
AU2011223900A1 (en) 2010-03-01 2012-09-13 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
AU2011250912A1 (en) 2010-05-12 2012-11-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
WO2012030540A2 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
CN103221536B (zh) 2010-08-31 2016-08-31 詹森生物科技公司 人胚胎干细胞的分化
KR101836850B1 (ko) 2010-08-31 2018-03-09 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
US9248120B2 (en) 2011-08-23 2016-02-02 The Board Of Trustees Of The Leland Stanford Junior University Reversing intestinal inflammation by inhibiting retinoic acid metabolism
RU2705001C2 (ru) 2011-12-22 2019-11-01 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки
MX354775B (es) 2012-03-07 2018-03-20 Janssen Biotech Inc Medios definidos para la expansion y el mantenimiento de celulas madre pluripotentes.
CN104334719B (zh) 2012-06-08 2018-02-13 詹森生物科技公司 人胚胎干细胞向胰腺内分泌细胞的分化
MX2015008578A (es) 2012-12-31 2015-09-07 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas en celulas endocrinas pancreaticas mediante el uso de relugadores de hb9.
DK2938722T3 (da) 2012-12-31 2022-02-14 Janssen Biotech Inc Suspension og klyngedannelse af humane pluripotente celler til differentiering til endokrine pankreasceller
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
KR102084561B1 (ko) 2012-12-31 2020-03-04 얀센 바이오테크 인코포레이티드 췌장 내분비 세포로의 분화를 위한 공기-액체 계면에서의 인간 배아 줄기세포의 배양
SG11201609473XA (en) 2014-05-16 2016-12-29 Janssen Biotech Inc Use of small molecules to enhance mafa expression in pancreatic endocrine cells
WO2017180361A1 (en) 2016-04-14 2017-10-19 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3404749B2 (ja) 1996-06-27 2003-05-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ N―[4―(ヘテロアリールメチル)フェニル]―ヘテロアリールアミン
AP869A (en) 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.
CN1596240A (zh) * 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
PL372356A1 (pl) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods

Similar Documents

Publication Publication Date Title
EP2396081B1 (en) Alkylamido compounds and uses thereof
JP5343267B2 (ja) タラロゾール代謝物
RU2007119380A (ru) Косметические продукты, предназначенные для ухода за собой, включающие соли дигидроксипропилтри (c1-c3алкил) аммония
JP2010519270A5 (enExample)
JP2010530373A5 (enExample)
JP2013515006A5 (enExample)
JP2007511546A5 (enExample)
JP2012144574A5 (enExample)
JP2009543799A5 (enExample)
JP2007302689A5 (enExample)
JP2007515465A5 (enExample)
MA30352B1 (fr) Pyridine [3,4-b] pyrazinones
JP2013533861A5 (enExample)
JP2015536947A5 (enExample)
JP2013523623A5 (enExample)
JP2006515613A5 (enExample)
JP2015522547A5 (enExample)
EP2308828A3 (en) CaSR antagonist
MX337396B (es) Metodo para el tratamiento de enfermedades del riñon poliquisticas con derivados de ceramica.
JP2018145180A5 (enExample)
EA022994B1 (ru) Способ подавления толерантности к опиоидному анальгетику
JP2007532632A5 (enExample)
JP2004502684A5 (enExample)
JP2008074845A5 (enExample)
JP2012524070A5 (enExample)